ICLR

ICLR

USD

ICON plc Ordinary Shares

$144.960+0.060 (0.041%)

Echtzeitkurs

Healthcare
Diagnostics & Research
Irland

Kursdiagramm

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$144.900

Hoch

$145.510

Tief

$142.840

Volumen

0.01M

Unternehmensfundamentaldaten

Marktkapitalisierung

11.8B

Branche

Diagnostics & Research

Land

Ireland

Handelsstatistiken

Durchschnittliches Volumen

1.15M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $133.28Aktuell $144.960Hoch $347.72

KI-Analysebericht

Zuletzt aktualisiert: 24. Apr. 2025
KI-generiertDatenquelle: Yahoo Finance, Bloomberg, SEC

ICLR: ICON plc Ordinary Shares - What's Happening and What to Watch

Stock Symbol: ICLR Generate Date: 2025-04-24 01:02:17

Alright, let's break down what's been going on with ICON plc (ICLR) based on the recent news and how the stock price has been moving. Think of this as getting the lowdown on the situation.

The Recent News Buzz

Looking at the news from the past few weeks, the overall feeling is definitely negative. It's not great news, to be honest.

The biggest chunk of headlines is about class action lawsuits. Multiple law firms (Schall, Levi & Korsinsky, Glancy Prongay & Murray, Gross, Robbins Geller, Rosen, Pomerantz, Kahn Swick & Foti, Kessler Topaz) are reminding investors who lost money during specific periods (like July 2023 to January 2025) that they can join these lawsuits. This kind of news usually pops up when there are allegations of securities fraud or misleading statements that might have hurt shareholders. Seeing so many firms involved and repeated reminders isn't a positive sign for investor confidence.

On top of the legal stuff, we've seen some analyst actions, and they aren't exactly cheering for the stock right now. TD Cowen and Barclays both downgraded their ratings on ICON (from Buy to Hold, and Overweight to Equal-Weight, respectively). Even analysts who kept a "Buy" rating, like Truist Securities and Citigroup, significantly lowered their price targets. This tells us that even the folks who were more optimistic before are now seeing less potential upside or more risk than they did previously. They're basically saying, "We still like the company, maybe, but we don't think the stock is worth as much as we thought it was."

There was one piece of news about a non-executive director appointment, but compared to the volume and nature of the lawsuit and analyst news, it's pretty minor in the grand scheme of things for the stock price right now.

So, the news vibe? Heavily negative, driven by legal troubles and analysts lowering their expectations.

Checking the Price Action

Now, let's look at what the stock price has actually been doing over the last 30 days or so. The historical data paints a clear picture that lines up with the negative news.

Back in late January, the stock was trading around the $200-$204 mark. It bounced around a bit in February, even touching the low $200s again. But starting in March, and really accelerating in April, the price has been on a pretty steep slide downwards.

We saw it drop from the $180s in early March, dip below $180, then below $170, and then take a significant tumble in April, falling from the $160s down into the $140s and recently hitting a low of $133.28 on April 22nd.

The current price is hovering just above that recent low. The trend is undeniably down over this period. It's been a rough ride for shareholders.

The AI prediction for today and the next couple of days suggests continued downward pressure overall, with a small predicted dip today (-1.07%), a tiny bump tomorrow (+0.02%), and then another predicted drop the day after (-3.13%). This forecast seems to align with the recent negative momentum we've seen.

Putting It All Together: Outlook & Ideas

Based on the combination of negative news sentiment (lawsuits, downgrades) and the clear downward trend in the stock price, the apparent near-term leaning for ICLR looks challenging. The data doesn't scream "buy" right now. It suggests caution is needed.

For existing investors, this situation might lean towards a 'hold' if you believe the company can navigate the legal issues and the analyst downgrades are overdone, or a 'sell' if you want to cut potential further losses given the strong negative signals. For someone thinking about buying in, the current picture doesn't offer a compelling reason to jump in based solely on this recent data.

If you were considering a potential entry point despite the negative news, perhaps looking for a bounce, the AI prediction mentions a support level around $135.91, and the recent low was $133.28. These levels could be areas where some buyers might step in, but it's a risky play given the overall trend and news. There's no strong signal here saying "buy now."

When it comes to managing risk, setting a potential stop-loss just below the recent low seems prudent. The recommendation data suggests $129.99 as a stop-loss level. Falling below the $133.28 low and then $129.99 would indicate the downtrend is likely continuing with force. Given the predicted downward pressure and lack of positive news, focusing on where to exit if things get worse seems more important than setting profit targets right now.

Company Context

Remember, ICON plc is a big player in the clinical research organization (CRO) space within the Healthcare sector. They help pharmaceutical and biotech companies run their clinical trials. The legal issues and analyst views are likely tied to their performance in this specific industry and any company-specific events or guidance that might have disappointed the market. The fact that analysts are lowering targets suggests they might see headwinds for ICON specifically or the CRO market generally.


Disclaimer: This analysis is based only on the provided data and is for informational purposes only. It is not financial advice. Stock markets are risky, and prices can go down as well as up. You should always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Ähnliche Nachrichten

PR Newswire

ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company...

Mehr anzeigen
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
Analyst Upgrades

TD Cowen Downgrades Icon to Hold, Lowers Price Target to $157

TD Cowen analyst Charles Rhyee downgrades Icon from Buy to Hold and lowers the price target from $254 to $157.

Mehr anzeigen
TD Cowen Downgrades Icon to Hold, Lowers Price Target to $157
PR Newswire

ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company...

Mehr anzeigen
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire

Class Action Filed Against ICON Public Limited Company (ICLR) Seeking Recovery for Investors - Contact Levi & Korsinsky

Levi & Korsinsky, LLP notifies investors in ICON Public Limited Company ("ICON " or the "Company") (NASDAQ: ICLR) of a class action securities...

Mehr anzeigen
Class Action Filed Against ICON Public Limited Company (ICLR) Seeking Recovery for Investors - Contact Levi & Korsinsky
PR Newswire

ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against ICON plc...

Mehr anzeigen
ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Analyst Upgrades

Truist Securities Maintains Buy on Icon, Lowers Price Target to $208

Truist Securities analyst Jailendra Singh maintains Icon with a Buy and lowers the price target from $262 to $208.

Analyst Upgrades

Barclays Downgrades Icon to Equal-Weight, Lowers Price Target to $165

Barclays analyst Luke Sergott downgrades Icon from Overweight to Equal-Weight and lowers the price target from $240 to $165.

KI-VorhersageBeta

KI-Empfehlung

Bärisch

Aktualisiert am: 28. Apr. 2025, 11:40

BärischNeutralBullisch

63.4% Konfidenz

Risiko & Handel

Risikostufe3/5
Mittleres Risiko
Geeignet für
Konservativ
Handelsleitfaden

Einstiegspunkt

$144.12

Gewinnmitnahme

$147.81

Stop-Loss

$138.40

Schlüsselfaktoren

PDI 5.0 liegt über MDI 4.3 mit ADX 8.7, was auf einen bullischen Trend hindeutet
Aktueller Preis ist extrem nah am Unterstützungsniveau ($144.69), was auf eine starke Kaufgelegenheit hindeutet
Handelsvolumen ist 11.2x Durchschnitt (15,062), was auf extrem starken Kaufdruck hindeutet
MACD 0.0669 liegt über der Signallinie 0.0590, was auf einen bullischen Crossover hindeutet

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.